HOOK

Hookipa Pharma Inc

HOOK, USA

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

https://www.hookipapharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
HOOK
stock
HOOK

Limited stock of Hook Norton’s barrel-aged stout - Beer Today

Read more →
HOOK
stock
HOOK

HOOK Stock Analysis and Forecast - IPO Market Watch & Small Budget Big Profits earlytimes.in

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-03-31)

Rating:

BUY

Target Price:

$2

Analyst Picks

Strong Buy

1

Buy

0

Hold

2

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-03-31)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.32

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-45.27 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-25.18 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

1.60 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Low

0.80

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 24.41% of the total shares of Hookipa Pharma Inc

1.

Baker Bros Advisors LP

(6.6632%)

since

2025/06/30

2.

Siren, L.L.C.

(4.6451%)

since

2025/06/30

3.

FMR Inc

(2.7383%)

since

2025/06/30

4.

Vanguard Group Inc

(2.466%)

since

2025/06/30

5.

Vanguard Total Stock Mkt Idx Inv

(1.8322%)

since

2025/07/31

6.

Fidelity VIP Growth Initial

(0.8316%)

since

2025/07/31

7.

Geode Capital Management, LLC

(0.6012%)

since

2025/06/30

8.

Fidelity Advisor Equity Growth I

(0.5481%)

since

2025/07/31

9.

Ikarian Capital, LLC

(0.4344%)

since

2025/06/30

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.3933%)

since

2025/07/31

11.

Renaissance Technologies Corp

(0.3736%)

since

2025/06/30

12.

Fidelity Growth Discovery

(0.3695%)

since

2025/07/31

13.

Fidelity Extended Market Index

(0.3167%)

since

2025/07/31

14.

Susquehanna International Group, LLP

(0.3055%)

since

2025/06/30

15.

Royal Bank of Canada

(0.2365%)

since

2025/06/30

16.

Dimensional Fund Advisors, Inc.

(0.1963%)

since

2025/06/30

17.

Morgan Stanley - Brokerage Accounts

(0.1578%)

since

2025/06/30

18.

State Street Corp

(0.1391%)

since

2025/06/30

19.

Northern Trust Corp

(0.1284%)

since

2025/06/30

20.

Fidelity Advisor Series Equity Gr

(0.1101%)

since

2025/07/31

21.

BlackRock Inc

(0.1004%)

since

2025/06/30

22.

BOOTHBAY FUND MANAGEMENT, LLC

(0.0958%)

since

2025/06/30

23.

Fidelity Total Market Index

(0.0923%)

since

2025/07/31

24.

Fidelity Series Total Market Index

(0.0767%)

since

2025/07/31

25.

Pacific Select Large-Cap Growth I

(0.0726%)

since

2025/08/31

26.

NT Ext Equity Mkt Idx Fd - NL

(0.0705%)

since

2025/06/30

27.

NT Ext Equity Mkt Idx Fd - L

(0.0552%)

since

2025/06/30

28.

Northern Trust Extended Eq Market Idx

(0.0552%)

since

2025/06/30

29.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0548%)

since

2025/06/30

30.

Spartan Total Market Index Pool G

(0.0468%)

since

2025/07/31

31.

Extended Equity Market Fund K

(0.0437%)

since

2025/06/30

32.

Spartan Extended Market Index Pool F

(0.037%)

since

2025/07/31

33.

Fidelity Nasdaq Composite Index

(0.0313%)

since

2025/07/31

34.

Tower Research Capital LLC

(0.0285%)

since

2025/06/30

35.

Vanguard U.S. Eq Idx ÂŁ Acc

(0.0212%)

since

2025/07/31

36.

Guardian Large Cap Fundamental Gr VIP

(0.0186%)

since

2025/06/30

37.

JPMorgan Chase & Co

(0.0067%)

since

2025/06/30

38.

Advisor Group Holdings, Inc.

(0.0041%)

since

2025/06/30

39.

Bank of America Corp

(0.0039%)

since

2025/06/30

40.

SIMPLEX TRADING, LLC

(0.0028%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-03-31

EPS Actual

-1.2192

EPS Estimate

-1.04

EPS Difference

-0.1792

Surprise Percent

-17.2308%

Investing Fit Scorecard

(Last Updated 2025-03-31)

Deep Value
Strong Deep Value(7.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(6.3)
GARP
Fair GARP(5.5)
Growth
Moderate Growth(4.5)
Momentum
Moderate Momentum(4)
Net Net
Strong Net-Net(9.5)
Quality
Moderate Quality(4)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-03-31)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-03-31)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-03-31)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.